Modulatable switch for selection of donor modified cells

US11213548B2 · kind B2 · utility

Assignees

• CSL Behring Gene Therapy, Inc. · US
• CSL Gene Therapy Pty Ltd. · AU

Inventors

• Christopher Walter ALMA · Parramatta, AU
• Jeffrey S. Bartlett · Columbus, US
• Louis Randall Breton · Tucson, US
• Geoffrey Phillip Symonds · Mandurah, AU
• Ming Yan · Los Angeles, US

Key dates

• Filing date: Aug 12, 2019
• Grant date: Jan 4, 2022
• Expiry date: Aug 12, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2239/48
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.